Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Teva Pharmaceutical

Catalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A Thread

Catalyst Pharmaceuticals: A One-Hit Wonder With Upside

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $17.55, making no change from the previous trading session.

Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know

Jounce Therapeutics

KalVista Pharma

Larimar Therapeutics Inc

Nektar Therapeutics

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

5 Stocks to Buy as the Drug Industry Rebounds in 2023

Eli Lilly

New data points to a looming recession in the U.S. In response, growth stocks took a step backward yesterday. Eli Lilly and Catalyst Pharmaceuticals are both capable of swimming against the current.

2 Top Growth Stocks That Can Withstand an Economic Downturn

Catalyst Pharmaceuticals expects improving results this year. Its new epilepsy medicine is likely to see continued healthy growth.

1 Growth Stock to Buy Before the Next Bull Market

Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.

Here is Why Growth Investors Should Buy Catalyst (CPRX) Now

Catalyst (CPRX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock

Cal-Maine Foods

New Jersey Resources

Defense is sometimes the best offense. In the spirit of March Madness and market volatility, it's time to get defensive as the banking crisis and market uncertainty fuel U.S. recession risks. As stocks fluctuate and the Fed suggests tighter credit conditions, investors are on edge with markets in flux following months of rate hikes.

Defense Is The Best Offense: 3 Stocks To Buy

Shares of pharma stock Catalyst jumped after earning 2023 sales forecasts exceeded analysts expectations. The post Pharma Stock's Earnings Impress Investors; Is It A Buy Now?

Pharma Stock's Earnings Impress Investors; Is It A Buy Now?

Amphastar Pharma

Enliven Therapeutics Inc

Horizon Pharma

Vertex Pharmaceuticals

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a Bet

Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?

Arista Networks

Terex

Invest in stocks like Catalyst Pharmaceuticals (CPRX), Terex (TEX) & Arista Networks (ANET) at the moment for superb earnings growth.

3 Stocks With Solid Earnings Growth to Buy Right Away

The average brokerage recommendation (ABR) for Catalyst (CPRX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable.

Is It Worth Investing in Catalyst (CPRX) Based on Wall Street's Bullish Views?

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Alicia Grande - VP, CFO, and Treasurer Patrick J. McEnany - Chairman, President, and CEO Jeff Del Carmen - Chief Commercial Officer Steven R.

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Call Transcript

Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates

Catalyst Pharmaceuticals topped fourth-quarter expectations and delivered strong guidance. In response, CPRX stock rose late Wednesday.

Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates

Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Catalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should Know

CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that an article was recently published in Epilepsia showed that perampanel reduces seizures with high effectivity in patients with rare genetic epileptic disease. The article is available online at https://onlinelibrary.wiley.com/doi/10.1111/epi.17530.

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

Costco

These two stocks are entirely different, but they both make shareholders richer.

News for Catalyst Pharmaceuticals Stock (CPRX)